NervGen's SCI Drug Shows 'Durable Improvement' in Chronic Injury

VANCOUVER, British Columbia – February 11, 2026 – NervGen Pharma Corp. is poised to present what could be a pivotal advancement in the treatment of spinal cord injury (SCI), a condition that has long challenged medical science. The clinical-stage biopharmaceutical company announced today it will share new data at a major patient advocacy symposium, detailing "durable improvement in function, independence, and quality of life" for individuals with chronic SCI who were treated with its lead therapeutic candidate, NVG-291.

The announcement sets the stage for a highly anticipated presentation at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium in Washington, D.C., a key gathering for the international SCI community. For patients and families who have been told that functional recovery plateaus within months of an injury, the prospect of a drug that can foster repair years later represents a significant shift in the landscape of hope and possibility.

A Landmark Presentation for a Long-Awaited Breakthrough

NervGen's President and CEO, Dr. Adam Rogers, is scheduled to take the stage on Sunday, February 15th, to lead a session titled, "Emerging Therapies with Challenges and Opportunities for the Future." The presentation is expected to go beyond high-level summaries, offering a detailed look at the clinical data from the company's Phase 1b/2a CONNECT SCI Study.

The choice of venue is itself significant. The Unite2Fight Paralysis symposium is not just a scientific conference; it's a nexus where leading researchers, clinicians, industry partners, policymakers, and, most importantly, individuals living with SCI and their advocates converge. Presenting positive data here provides a direct line of communication to the community most affected, and it amplifies the message within advocacy and policy circles, as the event includes a "Capitol Hill Advocacy Day" to lobby for increased research funding.

Adding to the session's weight is the composition of the panel, which includes Kristen Gill from the U.S. Food and Drug Administration (FDA). This offers a unique forum to discuss not just the scientific merits of a new therapy but also the complex regulatory pathways and challenges that lie ahead in bringing a potential treatment from the lab to the clinic.

Decoding the CONNECT SCI Study Data

The excitement surrounding NervGen's announcement is rooted in the specific, quantitative results from its chronic SCI study cohort. This portion of the trial enrolled individuals who were between one and ten years post-injury—a population for whom meaningful, spontaneous recovery is considered highly unlikely.

The study, which was randomized and placebo-controlled, showed that daily subcutaneous injections of NVG-291 over 12 weeks led to statistically significant biological changes. A key co-primary endpoint was met, demonstrating a three-fold increase in the strength of electrical connectivity between the brain and a crucial hand muscle (p=0.0155) for those receiving the drug compared to placebo. This wasn't just a signal on a machine; it translated into remarkable functional gains.

Participants treated with NVG-291 experienced an 825% mean improvement in functional hand use, a critical measure for independence in daily tasks like eating, writing, and self-care. Further analysis showed that 50% of individuals in the NVG-291 group saw clinically meaningful improvements in hand function, compared to just 10% in the placebo group. The biological basis for these improvements was supported by data showing the drug helped restore the balance between voluntary and involuntary motor pathways in both the upper and lower limbs.

Perhaps most compelling are the patient-reported outcomes, which paint a picture of real-world impact. Two-thirds of participants receiving NVG-291 reported improvements in bladder control, a life-altering benefit, compared to just 22% of the placebo group. More than half also noted a reduction in muscle spasticity. These improvements were not fleeting; follow-up interviews confirmed that the gains were durable, persisting long after the treatment period ended. Throughout the trial, NVG-291 was found to be generally safe and well-tolerated.

The Science of Repair: How NVG-291 Works

Unlike many other approaches, NVG-291 is not a stem cell therapy or a growth factor. It is a first-in-class "neuroreparative" peptide designed to unlock the central nervous system's own latent ability to heal. After a spinal cord injury, the body creates a scar rich in molecules called chondroitin sulfate proteoglycans (CSPGs), which act as a powerful "stop sign" for nerve cell regeneration.

NVG-291 works by targeting and inhibiting a receptor called protein tyrosine phosphatase sigma (PTPσ), essentially making neurons blind to the inhibitory signals sent by CSPGs. By removing this roadblock, the drug is believed to enable multiple natural repair mechanisms, including axonal regeneration (the regrowth of nerve fibers), neuroplasticity (the brain's ability to form new connections), and remyelination (the repair of the protective sheath around nerves).

This mechanism sets it apart from many competitors in the SCI pipeline. While cell therapies like Lineage Cell Therapeutics' OPC1 aim to replace damaged cells, and other drugs like Mitsubishi Tanabe's unasnemab target different inhibitory pathways, NervGen's approach of reactivating the body's intrinsic repair capacity offers a novel paradigm. The positive results in a chronic injury setting suggest this approach could be effective even long after the initial trauma.

Navigating the Path to Market

Demonstrating clinical efficacy is only one part of the journey. NervGen is also making strategic moves to navigate the complex regulatory and commercial landscape. The company has already secured Fast Track designation from the FDA and Orphan Drug designation from the European Medicines Agency (EMA) for NVG-291 in treating SCI. These designations are designed to expedite the development and review process for drugs addressing serious, unmet medical needs.

Following a productive meeting with the FDA in late 2025, NervGen is preparing for a crucial End-of-Phase 2 meeting in early 2026. This meeting will be critical for aligning with the agency on the design of a larger Phase 3 clinical trial, the final step required before seeking marketing approval.

The potential market is substantial. Hundreds of thousands of people suffer a spinal cord injury each year, with lifetime care costs running into the millions of dollars per patient. With no approved pharmaceuticals currently available to promote sustained functional recovery, a successful therapy like NVG-291 could not only transform patient lives but also become a blockbuster commercial product.

Corporate Momentum and Investor Outlook

The promising clinical data is being matched by a series of strategic corporate moves designed to position NervGen for its next phase of growth. The company recently uplisted to the Nasdaq, gaining access to a broader pool of investors, and formalized the appointment of Dr. Adam Rogers as its permanent CEO.

Financially, the company has been shoring up its balance sheet to fund its ambitious clinical plans. With cash and investments bolstered by a recent private placement, NervGen appears prepared for the significant expense of running a Phase 3 trial and continuing its subacute SCI study. Analyst sentiment remains positive, with a consensus "Buy" rating and price targets suggesting significant upside from its current market capitalization of approximately C$425 million.

As NervGen prepares to step into the spotlight at the symposium, it carries with it not just a set of compelling data points but the collective hopes of a community that has waited decades for a breakthrough. The road ahead is still long, but the data from NVG-291 suggests a new dawn for spinal cord injury treatment may finally be breaking.